Recomendações sobre a priorização de pacientes nas terapias ambulatoriais anti-SARS-CoV-2 ou estratégias preventivas quando há restrições logísticas ou de suprimentos.
13 Jan, 2022 | 12:10h
Comentário no Twitter
The rise in #Omicron infections may lead to supply constraints that limit the availability of anti-SARS-CoV-2 monoclonal antibodies or small molecule antivirals. We recommend prioritizing their use for patients at highest risk of clinical progression: https://t.co/IjcfP8AoOp
— NIH COVID-19 Treatment Guidelines (@NIHCOVIDTxGuide) December 27, 2021


